The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | NCRI AML18: CPX-351 vs standard daunorubicin & cytarabine plus fractionated GO in older pts with AML
Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, UK, comments on the results of the NCRI AML18 trial (NCT02272478), a randomized study comparing CPX-351 versus standard daunorubicin and cytarabine (DA) plus fractionated gemtuzumab ozogamicin (GO) in older adults with acute myeloid leukemia (AML) without adverse risk cytogenetics. The trial, which ran for eight years and closed in 2022, found that standard DA and fractionated GO emerged as the preferential treatment for this group of patients, with deeper remissions and superior overall and event-free survival rates. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
